Table 3 Virological results
From: Increased bronchiolitis burden and severity after the pandemic: a national multicentric study
RSV + n/n tested (%) | RSV + among ICU patients (% of ICU patients) | n (%) tested with panels; Rhinovirus + n (% of tested) | Patients presenting coinfections & RSV + (% out of RSV +) | Coinfections in patients without RSV | Coinfected patients in ICU (% of ICU patients); RSV + among these patients n (%) | Coinfected among MV n (% out of MV); RSV + n(%) | |
|---|---|---|---|---|---|---|---|
2018–2019 | 323/476 (68%); | 77/86 (89%) | 371 (77%); 60 (16%) | 47 (14%) | 14 (4%) | 19 (22%); 15 (17%) | 0/6 |
2019–2020 | 286/393 (73%) | 67/84 (80%) | 347 (88%); 52 (15%) | 48 (17%) | 20 (6%) | 18 (21%); 14 (17%) | 3/11 (27%); 2 (18%) |
2020–2021 | 3/34 (9%) | 1/6 (15%) | 29 (85%); 19 (65%) | 1 (33%) | 0 | 0; 0 | 0 |
2021–2022 | 457/560 (82%) | 112/122 (92%) | 387 (69%); 93 (22%) | 97 (21%) | 41 (10%) | 21 (17%); 17 (14%) | 0/6 |
2022–2023 | 749/946 (79%) | 180/210 (86%) | 715 (75%); 198 (27%) | 185 (25%) | 122 (17%) | 68 (32%); 52 (25%) | 15/38 (39%); 13 (34%) |
P-value | p < 0.001 | p < 0.001 | p < 0.001; p < 0.001 | p = 0.001 | p < 0.001 | p = 0.01; p = 0.08 |